Business
Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests SOUTH SAN FRANCISCO, Calif.--(BUSINESS
About this update from Veracyte, Inc.
[{"type":"text","content":"\nCollaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson1. The collaboration will include a focus on the NOBLE trial, a 9,000-patient, prospective, multicenter clinical study designed to distinguish genomic and other differences in lung cancer development and progression among patients with lung nodules detected by CT imaging.\n\nAs Veracyte plans for the 2021 launch of the first noninvasive nasal swab test to guide the work-up of patients with potentially cancerous lung nodules, this new study will position the company to develop future tests that benefit broader patient populations, including nonsmokers and those with pre-cancerous changes who are likely to develop lung cancer.\n\n“We are pleased to expand upon our collaboration in our goal of reducing lung cancer deaths,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “The NOBLE trial will provide a robust biorepository of genomic, clinical and outcome data, which we plan to translate into future tests that can help diagnose lung cancer at its earliest stages. It will also further our ability to address a nearly $40 billion global lung cancer market that is now more accessible to Veracyte through our own distributed testing platform, which enables advanced genomic testing to be performed locally by laboratories worldwide.”\n\nThe NOBLE trial is a prospective, multicenter study involving up to 50 sites globally. It is anticipated to enroll 9,000 individuals with lung nodules detected through CT imaging either via lung cancer screening or incidentally and will include patients who are benign at initial nodule diagnosis but who subsequently develop lung cancer. Researchers will collect nasal-swab, longitudinal blood and other samples, as well as imaging and clinical information at enrollment and at multiple points throughout the study. Patients will be followed according to current guidelines for three years or until a lung cancer diagnosis.\n\n“We are proud to participate in the NOBLE trial,” said Kim Rieger-Christ, Ph.D., chief scientific officer and director of translational research at Lahey...